Showing results (51-60 of 104) with videos related to

Sort By:
Pageof 11
Oncogene|April 11, 2026
Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancerBrittany N Heil, Garima Baral, Claire M Pfeffer, et al.
JCO Precision Oncology|January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung CancerJustin F Gainor, Diane Tseng, Satoshi Yoda, et al.
Cancer Discovery|April 7, 2021
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK ReactivationNoritaka Tanaka, Jessica J Lin, Chendi Li, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2021
Screening and Validation of Molecular Targeted RadiosensitizersHenning Willers, Xiao Pan, Nathalie Borgeaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2018
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug TargetKyung-A Song, Yasuyuki Hosono, Crystal Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K InhibitionSandra Misale, Jackson P Fatherree, Eliane Cortez, et al.
NPJ Precision Oncology|August 18, 2020
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibitionJessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinomaWilliam Zhao, Benjamin Kepecs, Navin R Mahadevan, et al.
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Pageof 11